Literature DB >> 18769112

Prevention of cancer by inhibiting aging.

Mikhail V Blagosklonny1.   

Abstract

Aging is associated with cancer, in particular with breast, prostate, colon, lung, stomach, bladder and skin cancer. This article discusses how aging predisposes one to cancer. In principle, inhibition of aging should delay cancer. But is it possible to slow aging? As recently proposed, the nutrient-sensing TOR (target of rapamycin) pathway is involved in cellular and organismal aging. In rodents, certain conditions that interfere with the TOR pathway slow aging and prevent cancer. Retrospective analysis of clinical data reveals that inhibitors of TOR prevent cancer in humans. This article envisions a potential clinical use of TOR inhibitors in order to slow aging and delay cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18769112     DOI: 10.4161/cbt.7.10.6663

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  62 in total

1.  Critical role of mTOR in calcineurin inhibitor-induced renal cancer progression.

Authors:  Aninda Basu; Pallavi Banerjee; Soumitro Pal
Journal:  Cell Cycle       Date:  2012-02-15       Impact factor: 4.534

Review 2.  Gadd45 proteins: relevance to aging, longevity and age-related pathologies.

Authors:  Alexey A Moskalev; Zeljka Smit-McBride; Mikhail V Shaposhnikov; Ekaterina N Plyusnina; Alex Zhavoronkov; Arie Budovsky; Robi Tacutu; Vadim E Fraifeld
Journal:  Ageing Res Rev       Date:  2011-10-05       Impact factor: 10.895

3.  When Anti-Aging Studies Meet Cancer Chemoprevention: Can Anti-Aging Agent Kill Two Birds with One Blow?

Authors:  Noriko N Yokoyama; Andria Denmon; Edward M Uchio; Mark Jordan; Dan Mercola; Xiaolin Zi
Journal:  Curr Pharmacol Rep       Date:  2015-04-14

4.  Ser2481-autophosphorylated mTOR colocalizes with chromosomal passenger proteins during mammalian cell cytokinesis.

Authors:  Alejandro Vazquez-Martin; Tamara Sauri-Nadal; Octavio J Menendez; Cristina Oliveras-Ferraros; Sílvia Cufí; Bruna Corominas-Faja; Eugeni López-Bonet; Javier A Menendez
Journal:  Cell Cycle       Date:  2012-10-24       Impact factor: 4.534

5.  Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin.

Authors:  Irina G Popovich; Vladimir N Anisimov; Mark A Zabezhinski; Anna V Semenchenko; Margarita L Tyndyk; Maria N Yurova; Mikhail V Blagosklonny
Journal:  Cancer Biol Ther       Date:  2014-02-20       Impact factor: 4.742

6.  Sex differences in aging, life span and spontaneous tumorigenesis in 129/Sv mice neonatally exposed to metformin.

Authors:  Vladimir N Anisimov; Irina G Popovich; Mark A Zabezhinski; Peter A Egormin; Maria N Yurova; Anna V Semenchenko; Margarita L Tyndyk; Andrey V Panchenko; Alexandr P Trashkov; Andrey G Vasiliev; Nikolai V Khaitsev
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

7.  Aging: past, present and future.

Authors:  Mikhail V Blagosklonny; Judith Campisi; David A Sinclair
Journal:  Aging (Albany NY)       Date:  2009-01-07       Impact factor: 5.682

8.  Inhibition of S6K by resveratrol: in search of the purpose.

Authors:  Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2009-06-29       Impact factor: 5.682

9.  Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential.

Authors:  Zoya N Demidenko; Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2009-12-31       Impact factor: 5.682

10.  Why human lifespan is rapidly increasing: solving "longevity riddle" with "revealed-slow-aging" hypothesis.

Authors:  Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2010-04-18       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.